Is this increasingly popular weight management tactic an option for your patients with type 2 diabetes? Primary care physician Jay Shubrook and Jamie Katuna explain in this illustrative case study.
Three-quarters of people who undergo islet transplantation for type 1 diabetes have sustained graft survival with associated improvements in glucose control, insulin requirements, and hypoglycemia incidence 10 years later, research shows.
Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.
Real-world, off-label sodium–glucose cotransporter 2 inhibitor use is uncommon in people with type 1 diabetes but appears to be associated with a higher than expected rate of diabetic ketoacidosis when compared with clinical trials, US researchers report.
People with type 1 diabetes using the Tandem Control-IQ hybrid closed-loop insulin delivery system spent significantly more time within their target blood glucose range than people using a sensor-augmented insulin pump during 6 months of use in the iDCL trial.
The effect of glycemic control on all‐cause mortality risk depends on diabetes duration in people aged 65 years and older with type 2 diabetes, study findings indicate.
The most recently approved class of glucose-lowering medication may not be reaching people with additional health conditions who would particularly benefit from these medications, a study of over a million US patients with diabetes suggests.
A pilot study published in JAMA shows that although heat stress is a potential issue for men with type 2 diabetes who wish to exercise, they may be able to acclimatize through repeated brief exposures.
Offering free medications to patients who struggle to afford them improves adherence, but with mixed effects on surrogate disease outcomes, report the CLEAN Meds researchers.
Is this increasingly popular weight management tactic an option for your patients with type 2 diabetes? Primary care physician Jay Shubrook and Jamie Katuna explain in this illustrative case study.
Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
Research published in JAMA supports a beneficial cardiovascular safety profile for metformin relative to sulfonylureas in people with mild or moderate kidney dysfunction.
Results of the DEFINE-HF trial indicate that add-on dapagliflozin treatment may improve health status among people with established heart failure and reduced ejection fraction.
